Home NIV in COPD: Cost saver or cost driver?

Key facts

  • Home NIV in COPD: Cost saver or cost driver
  • With Dr Patrick Murphy & Dr Eline Gantzhorn
  • May 26th, 2021
  • 4:00 pm to 5:00 pm CET

ResMed Live Webinar

on May 26th, 2021 from 4:00 pm to 5:00 pm (CEST time)
Register

Content

Join us for a discussion between Dr Patrick Murphy, principal investigator of the HOT-HMV study and Dr Eline Gantzhorn from Vejle Hospital, Denmark about the health economic aspect of home NIV in COPD.

Home NIV has benefits for COPD patients with persistent hypercapnia.¹² The therapy can reduce mortality,¹ the risk of hospital admissions² and improve quality of life¹ in these patients.

That said, can improved clinical outcomes be achieved whilst optimizing cost of care?

References:

1 Köhnlein et al, Lancet Respir Med. 2014;2(9):698-705.
2 Murphy et al. JAMA. 2017 Jun 6;317(21):2177-2186

Speakers

Dr Patrick Murphy

and his team assess the cost effectiveness of home NIV for COPD patients in their clinical practice at Guys' and St Thomas Hospital in London. They find that it provides a favorable QALY (quality adjusted life years - an estimate looking at both quality of life and associated costs of treatment).

Dr Eline Gantzhorn

works at Vejle Hospital in Denmark. Since 2015, the Danish lung society recommends home NIV in stable hypercapnic COPD patients. Nationally, though, financial barriers remain for the use of home NIV in COPD patients.